NCT05425576View on ClinicalTrials.gov

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Malignant Pleural Mesothelioma
Interventions
DRUG

OT-101

OT-101 in combination of pembrolizumab

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors

Lead Sponsor

Oncotelic Inc.
All Listed Sponsors
lead

Oncotelic Inc.

INDUSTRY